Blackstone puts $250M into Anagram to tackle cystic fibrosis complication

Blackstone Life Sciences is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of pills many cystic fibrosis patients have to take each day. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the…

Source: Endpoints News